Joint Clinical Trials Office
The underappreciated role of atherosclerotic cardiovascular disease in primary biliary cholangitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
A Phase III, Multisite, Double-Blinded Randomized Trial of BNT327 In Combination with Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab In Combination with Chemotherapy In Participants with First-Line Extensive-Stage Small-Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
EoE-201, A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects with Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20mg to Evaluate the Safety and Efficacy of Vonoprazan 20mg Compared to Placebo
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 21, 2026
MASTER SCREENING STUDY TO DETERMINE POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH ALZHEIMER’S DISEASE AS ASSESSED BY THEIR BIOMARKER STATUS AND COGNITION
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 30, 2026
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 30, 2026
Pilot Randomized Trial of Health Coaching for People with Rheumatoid Arthritis to Improve Mental Well Being
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 1, 2026
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 5, 2026
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2026
Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies (RENAL AID)
Study Status:
Open to Enrollment
Primary Investigator:
Alan Perlman, M.D.
Date: March 15, 2016